Figures & data
Figure 1 Decitabine (C12)2 synthesis.
Abbreviations: DCC, dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino) pyridine.
![Figure 1 Decitabine (C12)2 synthesis.Abbreviations: DCC, dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino) pyridine.](/cms/asset/2a231959-43f3-439d-9d7b-bf1324108eea/dijn_a_12190710_f0001_b.jpg)
Figure 2 Preparation of lipid nanocapsules loaded with decitabine (C12)2 by phase inversion temperature.
Abbreviation: LNCs, lipid-core nanocapsules.
![Figure 2 Preparation of lipid nanocapsules loaded with decitabine (C12)2 by phase inversion temperature.Abbreviation: LNCs, lipid-core nanocapsules.](/cms/asset/d9b8a8d1-df34-4b43-9660-f5c51698b33c/dijn_a_12190710_f0002_c.jpg)
Table 1 Gradient elution in the LC-MS/MS method
Table 2 Physiochemical characterizations of blank and loaded LNC formulations (n=3)
Figure 3 Physiochemical behavior of decitabine (C12)2 PBS-loaded LNCs in PBS at 37°C for 48 hours (n=3). Drug loading and residual decitabine (C12)2 concentration remained unchanged for the first 12 hours and decreased thereafter (A), whereas the size and PDI remained unchanged for 48 hours (B).
Abbreviations: LNC, lipid-core nanocapsule; PDI, polydispersity index.
![Figure 3 Physiochemical behavior of decitabine (C12)2 PBS-loaded LNCs in PBS at 37°C for 48 hours (n=3). Drug loading and residual decitabine (C12)2 concentration remained unchanged for the first 12 hours and decreased thereafter (A), whereas the size and PDI remained unchanged for 48 hours (B).Abbreviations: LNC, lipid-core nanocapsule; PDI, polydispersity index.](/cms/asset/a1b141d1-0bdf-45c8-ada9-a13ff7a3b9fb/dijn_a_12190710_f0003_b.jpg)
Figure 4 Decitabine (C12)2 stability in human plasma. Decitabine (C12)2-loaded LNCs were incubated in human plasma at 37°C for 24 hours. The decitabine-(C12)2 concentration at the initial timepoint (T0) was considered to be 100% (n=3).
Abbreviation: LNCs, lipid-core nanocapsules.
![Figure 4 Decitabine (C12)2 stability in human plasma. Decitabine (C12)2-loaded LNCs were incubated in human plasma at 37°C for 24 hours. The decitabine-(C12)2 concentration at the initial timepoint (T0) was considered to be 100% (n=3).Abbreviation: LNCs, lipid-core nanocapsules.](/cms/asset/2ec6fb37-65cf-4ac1-a0f5-acc29cf581d1/dijn_a_12190710_f0004_b.jpg)
Figure 5 Cell proliferation study of HEL following exposure to various concentrations of blank LNCs (indicated below each bar graph), decitabine solution, decitabine (C12)2-loaded LNCs, or decitabine (C12)2 solution. Cells cultured with medium alone were considered to correspond to 100% viability (n=3 plates, quadruplicate).
Note: *P<0.05 Mann–Whitney test.
Abbreviations: HEL, human erythroleukemia cell line; LNCs, lipid-core nanocapsules.
![Figure 5 Cell proliferation study of HEL following exposure to various concentrations of blank LNCs (indicated below each bar graph), decitabine solution, decitabine (C12)2-loaded LNCs, or decitabine (C12)2 solution. Cells cultured with medium alone were considered to correspond to 100% viability (n=3 plates, quadruplicate).Note: *P<0.05 Mann–Whitney test.Abbreviations: HEL, human erythroleukemia cell line; LNCs, lipid-core nanocapsules.](/cms/asset/93158854-37cc-4dcd-9dee-d26336ce4161/dijn_a_12190710_f0005_b.jpg)
Figure 6 Cell-cycle analysis of HEL cells following exposure to RPMI (A), blank LNCs (B), decitabine solution (C), or decitabine (C12)2-loaded LNCs (D) also as expressed as a percentage of cells blocked in G2/M phase (E) (n=3 plates, in triplicate).
Note: *P<0.05 Mann–Whitney test vs cells treated with RPMI.
Abbreviations: HEL, human erythroleukemia cell line; LNCs, lipid-core nanocapsules; RPMI, Roswell Park Memorial Institute medium 1640.
![Figure 6 Cell-cycle analysis of HEL cells following exposure to RPMI (A), blank LNCs (B), decitabine solution (C), or decitabine (C12)2-loaded LNCs (D) also as expressed as a percentage of cells blocked in G2/M phase (E) (n=3 plates, in triplicate).Note: *P<0.05 Mann–Whitney test vs cells treated with RPMI.Abbreviations: HEL, human erythroleukemia cell line; LNCs, lipid-core nanocapsules; RPMI, Roswell Park Memorial Institute medium 1640.](/cms/asset/419db3dd-fe62-42f0-8e56-efb35845d7e6/dijn_a_12190710_f0006_c.jpg)
Table 3 Main pharmacokinetic parameters of decitabine and decitabine (C12)2 following IV administration of 5 mg/kg decitabine or 12.5 mg/kg decitabine (C12)2
Figure 7 Evolutions of plasma concentrations of active pharmaceutical ingredients over time following IV bolus administration of a decitabine solution or a decitabine (C12)2-loaded LNCs solution.
Note: Results are presented as mean±SEM (n=5 for each group).
Abbreviations: API, active pharmaceutical ingredient; DAC, decitabine; IV, intravenous; LNCs, lipid-core nanocapsules; SEM, standard error of the mean.
![Figure 7 Evolutions of plasma concentrations of active pharmaceutical ingredients over time following IV bolus administration of a decitabine solution or a decitabine (C12)2-loaded LNCs solution.Note: Results are presented as mean±SEM (n=5 for each group).Abbreviations: API, active pharmaceutical ingredient; DAC, decitabine; IV, intravenous; LNCs, lipid-core nanocapsules; SEM, standard error of the mean.](/cms/asset/9f5b3308-0fe8-4771-ae79-22d150ad59c4/dijn_a_12190710_f0007_b.jpg)